Rankings · Price against the business
Most free cash flow per dollar of price
Graded A or B, ranked by free cash flow over the last twelve months divided by market value. Banks and insurers are left out, and yields above 50% are treated as data problems rather than bargains.
152 companies meet this test
Figures as of October 1, 2026
| # | Company | Grade | Free cash flow yield | P/E | Revenue growth | Market value |
|---|---|---|---|---|---|---|
| 1 | AMNAMN HEALTHCARE SERVICES, INC. | B | 32.5% | 12.99 | -8% a year | $1.4B |
| 2 | ARDTArdent Health, Inc. | A | 20.4% | 19.29 | +8% a year | $1.5B |
| 3 | NUTXNUTEX HEALTH INC. | B+ | 19.1% | 8.31 | — | $1.4B |
| 4 | TAKTakeda Pharmaceutical Company Limited | B | 18.6% | 43.25 | +4% a year | $29.7B |
| 5 | GRFSGrifols SA | A | 17.9% | 27.95 | +7% a year | $5B |
More rankings
A ranking orders companies by one stated measure. It is not a recommendation, and it says nothing about whether any share price is reasonable.